CompletedPhase 2NCT02197767
Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis
Studying Non-amyloid fibrillary glomerulopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Stephen B. Erickson, M.D.Mayo Clinic
- Intervention
- rituximab(drug)
- Enrollment
- 11 target
- Eligibility
- 18-79 years · All sexes
- Timeline
- 2014 – 2017
Study locations (1)
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
Collaborators
Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02197767 on ClinicalTrials.govOther trials for Non-amyloid fibrillary glomerulopathy
Additional recruiting or active studies for the same condition.